Detalhe da pesquisa
1.
A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
Br J Dermatol;
186(5): 849-860, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34811721
2.
Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
J Am Acad Dermatol;
86(3): 581-589, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34252464
3.
Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.
J Drugs Dermatol;
21(2): 122-126, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35133112
4.
Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
J Drugs Dermatol;
21(4): 399-407, 2022 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35389589
5.
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Dermatol Ther;
34(2): e14808, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33491259
6.
Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies.
J Drugs Dermatol;
20(4): 394-401, 2021 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33852247
7.
The experience of itch in children with psoriasis: A qualitative exploration of the Itch Numeric Rating Scale.
Pediatr Dermatol;
38(2): 405-412, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33336430
8.
Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
J Am Acad Dermatol;
82(5): 1138-1149, 2020 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31884091
9.
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
J Am Acad Dermatol;
82(4): 927-935, 2020 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31712178
10.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Qual Life Res;
29(2): 369-380, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31655974
11.
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Acta Derm Venereol;
100(1): adv00006, 2020 01 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31620802
12.
Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort.
BMC Dermatol;
20(1): 3, 2020 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32434510
13.
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.
J Sex Med;
15(11): 1645-1652, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30415816
14.
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
J Am Acad Dermatol;
79(2): 294-301.e6, 2018 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29653208
15.
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
Acta Derm Venereol;
98(1): 98-102, 2018 Jan 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28929168
16.
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
BMC Dermatol;
18(1): 4, 2018 06 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29954363
17.
Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
J Drugs Dermatol;
16(12): 1246-1252, 2017 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29240860
18.
Real-world clinical and economic outcomes for daily teriparatide patients in Japan.
J Bone Miner Metab;
34(6): 692-702, 2016 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26661475
19.
Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients.
Health Qual Life Outcomes;
14: 25, 2016 Feb 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26896284
20.
Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.
Clin Orthop Relat Res;
474(5): 1234-44, 2016 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26932738